Merck (MRK) Reports Positive Phase 2b Tulisokibart Results In Hidradenitis Suppurativa

Merck (NYSE:MRK) reported positive Phase 2b results for tulisokibart in moderate to severe hidradenitis suppurativa on 1 October 2026. The investigational anti TL1A monoclonal antibody met its Phase 2b efficacy goals in patients with this chronic inflammatory skin condition. Merck stated that tulisokibart's Phase 2b data support advancing the program into Phase 3 trials in hidradenitis suppurativa. There is much more to Merck's story than the tulisokibart Phase 2b milestone in hidradenitis...